Cargando…

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration

PURPOSE: The relationship between incidences of neutropenia and 10-hydroxy-7-ethyl camptothecin (SN38) exposure was explored using SN38 pharmacokinetic and neutrophil count data from toxicology studies of etirinotecan pegol (EP) and irinotecan in beagle dogs. METHODS: Dogs received four weekly intra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sy, S. Kenneth, Sweeney, Theresa D., Ji, Chunmei, Hoch, Ute, Eldon, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225190/ https://www.ncbi.nlm.nih.gov/pubmed/27904955 http://dx.doi.org/10.1007/s00280-016-3192-6

Ejemplares similares

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
por: Sy, Sherwin K. B., et al.
Publicado: (2018)

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
por: Hoch, Ute, et al.
Publicado: (2014)

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
por: Cortés, Javier, et al.
Publicado: (2016)

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
por: Nagpal, Seema, et al.
Publicado: (2015)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
por: Feng, Haiyang, et al.
Publicado: (2014)

Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients
por: Zhang, Shuxiao, et al.
Publicado: (2023)

Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model
por: Lewis, Andrew L., et al.
Publicado: (2012)

Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
por: Nakamura, Fumihiko, et al.
Publicado: (2019)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
por: Takada, Ryoji, et al.
Publicado: (2023)

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration
por: Din, Fakhar ud, et al.
Publicado: (2017)

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
por: Adkins, Chris E., et al.
Publicado: (2015)

Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data
por: Knerr, Sarah, et al.
Publicado: (2017)

Improving Time to Antibiotic Administration in Pediatric Patients with Fever and Suspected Neutropenia
por: Balsley, Kate, et al.
Publicado: (2021)

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study
por: Ueoka, H, et al.
Publicado: (1999)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report
por: Kanno, Ryota, et al.
Publicado: (2023)

Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy
por: Chandar, Manisha, et al.
Publicado: (2015)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin
por: Hellwig, Martin D., et al.
Publicado: (2021)

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan
por: Keil, Andreas, et al.
Publicado: (2016)

A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer
por: Hesse, Janina, et al.
Publicado: (2021)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Optimizing Time to Antibiotic Administration in Children with Possible Febrile Neutropenia through Quality Improvement Methodologies
por: Burns, Beech, et al.
Publicado: (2019)

Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies
por: Adedeji, Adeyemi O., et al.
Publicado: (2022)

Effect of time of administration on cholesterol-lowering by psyllium: a randomized cross-over study in normocholesterolemic or slightly hypercholesterolemic subjects
por: Van Rosendaal, Guido MA, et al.
Publicado: (2004)

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
por: Ichikawa, W, et al.
Publicado: (2015)

Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation
por: Yang, Wenqian, et al.
Publicado: (2019)

A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver
por: Melancon, Marites P., et al.
Publicado: (2021)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)

Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
por: Misaki, M., et al.
Publicado: (1998)

Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer
por: Burton, J.H., et al.
Publicado: (2016)

Time to antibiotic administration in children with febrile neutropenia: Report from a low middle-income country
por: Todurkar, Namrata, et al.
Publicado: (2021)

A Rare Adverse Event after CoronaVac(®)Administration: Neutropenia in a Kidney Transplant Recipient
por: Artan, Ayşe Serra, et al.
Publicado: (2022)

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Comparative educational administration
Publicado: (1962)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
por: Tsavaris, Nicolas, et al.
Publicado: (2002)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vdh3rijdm7utv213guaar6meeh